- Report
- September 2022
- 239 Pages
Global
From €6734EUR$7,500USD£5,735GBP
- Report
- January 2022
- 224 Pages
Global
From €6240EUR$6,950USD£5,314GBP
- Report
- May 2024
- 298 Pages
Global
From €7138EUR$7,950USD£6,079GBP
- Report
- May 2023
- 450 Pages
Global
From €4489EUR$5,000USD£3,823GBP
- Report
- April 2023
- 350 Pages
Global
From €2918EUR$3,250USD£2,485GBP
- Drug Pipelines
- December 2022
- 30 Pages
Global
From €2918EUR$3,250USD£2,485GBP
- Drug Pipelines
- December 2022
- 30 Pages
Global
From €2918EUR$3,250USD£2,485GBP
- Report
- December 2024
- 85 Pages
Spain
From €2671EUR$2,975USD£2,275GBP
€3142EUR$3,500USD£2,676GBP
- Report
- August 2024
- 85 Pages
India
From €2671EUR$2,975USD£2,275GBP
€3142EUR$3,500USD£2,676GBP
- Report
- February 2024
- 170 Pages
Global
From €3434EUR$3,825USD£2,925GBP
€4040EUR$4,500USD£3,441GBP
- Report
- October 2023
- 138 Pages
North America
From €3053EUR$3,400USD£2,600GBP
€3591EUR$4,000USD£3,058GBP
- Report
- February 2024
- 120 Pages
Global
From €4265EUR$4,750USD£3,632GBP
- Report
- April 2023
- 110 Pages
Global
From €4265EUR$4,750USD£3,632GBP
- Report
- April 2023
- 119 Pages
Global
From €4265EUR$4,750USD£3,632GBP
- Report
- July 2023
- 290 Pages
Global
From €3232EUR$3,600USD£2,753GBP
- Report
- April 2023
- 326 Pages
Global
From €3232EUR$3,600USD£2,753GBP
- Report
- November 2022
- 206 Pages
Global
From €3232EUR$3,600USD£2,753GBP
- Report
- May 2022
- 188 Pages
Global
From €3232EUR$3,600USD£2,753GBP
- Report
- February 2022
- 185 Pages
Global
From €3232EUR$3,600USD£2,753GBP
- Report
- November 2020
- 450 Pages
Global
From €4399EUR$4,900USD£3,747GBP

Pembrolizumab is a type of oncology drug used to treat certain types of cancer. It is a monoclonal antibody, which works by targeting and blocking a protein called PD-1, which is found on the surface of some cancer cells. This helps the body's immune system to recognize and attack the cancer cells. Pembrolizumab is used to treat a variety of cancers, including melanoma, non-small cell lung cancer, head and neck cancer, Hodgkin lymphoma, and urothelial carcinoma. It is also used in combination with other drugs to treat certain types of advanced or metastatic cancers.
Pembrolizumab is approved by the US Food and Drug Administration (FDA) and is available in the US and other countries. It is typically administered intravenously, and the dosage and duration of treatment depend on the type and stage of cancer being treated.
Some companies in the Pembrolizumab market include Merck & Co., Inc., Bristol-Myers Squibb, AstraZeneca, and Roche. Show Less Read more